US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
SNDK
$1,719.99
▲+0.00%
NVDA
$233.95
▲+0.00%
SPCX
$158.96
▲+0.00%
AMD
$633.91
▲+0.00%
WDC
$415.29
▲+0.00%
MSTR
$160.01
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Organon & Co. Common Stock
(NY:
OGN
)
13.72
UNCHANGED
Delayed Quote
Updated: 7:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Organon & Co. Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
20
21
Next >
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
↗
September 06, 2024
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris.
Via
Benzinga
3 Cheap High Dividend Stocks For Passive Income
↗
August 30, 2024
These undervalued high yield stocks could return over 10% per year.
Via
Talk Markets
Organon Stock Sees Relative Strength Rating Rise To 91
↗
August 27, 2024
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before.
Via
Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
↗
August 20, 2024
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier.
Via
Investor's Business Daily
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
August 20, 2024
From
Organon & Co.
Via
Business Wire
High Dividend 50: Organon & Co.
↗
June 27, 2024
Organon & Co.’s current annual dividend is $1.12 per share. At around $20 per share, Organon stock has a high yield of 5.4%.
Via
Talk Markets
OGN Stock Earnings: Organon Beats EPS, Misses Revenue for Q2 2024
↗
August 06, 2024
OGN stock results show that Organon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
Organon Reports Results for the Second Quarter Ended June 30, 2024
August 06, 2024
From
Organon & Co.
Via
Business Wire
Jim Cramer Says No To This Health Care Stock, Recommends Holding On To Constellation Energy: 'It's Up A Huge Amount'
↗
July 30, 2024
Jim Cramer said Constellation Energy is a "solar play that is a very good company. It's up a huge amount versus a lot of other stocks."
Via
Benzinga
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
July 09, 2024
From
Organon & Co.
Via
Business Wire
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
↗
July 06, 2024
These exchange-traded funds should keep the income flowing in regularly.
Via
The Motley Fool
Topics
ETFs
Value Investing Is Back! 3 Stocks With Strong Fundamentals to Buy Now
↗
June 26, 2024
Uncover three top value stocks to buy with robust fundamentals for stable long-term growth amid turbulence.
Via
InvestorPlace
3 Stocks With Mouthwatering Dividends You Can Buy Right Now
↗
June 08, 2024
These stocks offer great dividends and more.
Via
The Motley Fool
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
May 24, 2024
From
Organon & Co.
Via
Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
↗
May 10, 2024
Via
Benzinga
Organon Announces Pricing of $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Organon Announces Proposed $1.0 Billion Senior Notes Offering
May 07, 2024
From
Organon & Co.
Via
Business Wire
Organon Beats On Q1, Women's Health Leads the Charge
↗
May 02, 2024
Organon reported 5% increase in Q1 2024 revenue of $1.622 billion, beating consensus. EPS of $1.22 and dividend of $0.28 declared.
Via
Benzinga
OGN Stock Earnings: Organon Beats EPS, Beats Revenue for Q1 2024
↗
May 02, 2024
OGN stock results show that Organon beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Organon Reports Results for the First Quarter Ended March 31, 2024
May 02, 2024
From
Organon & Co.
Via
Business Wire
7 Sleeper Stocks to Buy Before Wall Street Wakes Up: April 2024
↗
May 01, 2024
While these sleeper stocks to buy don’t attract the spotlight, the lack of attention makes these ideas even more enticing.
Via
InvestorPlace
3 Healthcare Stocks With the Potential to Triple Your Investment by 2026
↗
May 01, 2024
Learn how these three healthcare stocks offer sharp opportunities in pharmaceuticals, healthcare services, and biotechnology.
Via
InvestorPlace
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
April 08, 2024
From
Organon & Co.
Via
Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
April 08, 2024
From
Organon & Co.
Via
Business Wire
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
↗
March 13, 2024
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Turn $500 into a Fortune: 3 Top Stock Picks for March’s Million-Dollar Rally
↗
March 07, 2024
Here are three top stock picks for rally have their grip in travel, packaged foods, meats and pharmaceuticals.
Via
InvestorPlace
5 Value Stocks In The Healthcare Sector
↗
March 04, 2024
Via
Benzinga
Drug Maker Organon Stock Scores Relative Strength Upgrade
↗
February 28, 2024
In a welcome move, drug maker Organon stock saw its Relative Strength Rating rise from 66 to 71 on Wednesday.
Via
Investor's Business Daily
Under the Radar: 3 Overlooked Stocks Ready to Dominate the Market
↗
February 26, 2024
Explore growth strategies of overlooked stocks with strong fundamentals in strategic investments and market expansion.
Via
InvestorPlace
New York Attorney General Urges FDA Action On Widely Used Asthma Drug's Concerns Over Pediatric Safety
↗
February 26, 2024
The Attorney General of New York, Letitia James, has called on the FDA to address safety risks associated with the widely used asthma and allergy medicine Singulair (montelukast).
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
17
...
20
21
Next >
